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Introduction
presence of cofactors within 3-4 years. These cofactors include high-risk HPV types; cigarette smoking; immunosuppression; cervical infections, such as chlamydia and Herpes simplex virus (HSV); oral contraceptive pill use; multiparity; and genetic factors. Spontaneous regression rates decrease after HGSIL development, and 30-70% of these cases progress to invasive cancer within approximately 10 years. In other words, 15% of women with HPV develop cervical intraepithelial neoplasia (CIN) within 7 years. Regression and progression rates of CIN are shown in Table 2 . Development of invasive cancer is established at a rate of 1-3% after high-risk HPV transmission, and the required time period is approximately 25-40 years. Human papilloma virus testing was found to be positive in 96.6% of patients with cervical cancer. HPV types that are mostly associated with the development of cervical squamous cancer are HPV 16 (53.5%), HPV 18 (17.2%), HPV 45 (6.2%), and HPV 31 (2.9%). These rates and types other than HPV 16 and HPV 18 can differ by countries. However, HPV 16 and HPV 18 are identified as being mostly associated with 70.7% of cervical cancers. HPV 18 is mostly associated with cervical adenocarcinoma. In a retrospective study evaluating data from 10,575 patients with invasive cervical cancer conducted by de Sanjose et al. (3) , it was reported that HPV 16 and HPV 18 were positive in 71% of patients. In the same study, HPV 16, HPV 18, and HPV 45 were identified as positive in 94% of cervical adenocarcinoma cases. In the study of Usubütün et al. (4) , they identified HPV types in cervical cancer in our country, and they found the ratios of types as follows: HPV 16 was 64.7%, HPV 18 was 9.9%, HPV 45 was 9.9%, HPV 31 was 3%, and HPV 33 was 2.2%.
A. HPV testing
Human papilloma virus (HPV) is believed to initiate tumorigenesis in cervical carcinoma. HPV is also associated with some anal, vaginal, vulvar, oral, and skin cancers other than cervix. It is suggested to be associated with 4% of all cancers throughout the body (5). According to western society statistics, 50-80% of women are infected with HPV at least once in their lives (6) . While the infection rate is higher in young patients (<25 years), it declines in the 30s and 40s and shows a slight increase in the postmenopausal period (7, 8) . Oncogenic HPV type is present in 10% of the 20-65-year-old population. The latent infection prevalence is 8-15% (9) . Transient HPV infection is not of importance in cancer development, whereas HPV DNA positivity is a risk factor for cervical cancer (10) . Since colposcopy is recommended for HPV 16-positive cases, HPV tests specific for HPV 16 and HPV 18 are available in addition to oncogenic HPV testing. For women with ASC-US cytology and (-) HPV result, colposcopy and biopsy are unnecessary, and follow-up cytology at regular intervals is acceptable. If HPV is positive, immediate colposcopy should be performed as a secondary management. A positive (+) test result in a patient with ASC-US smear suggests that the patient has HGSIL at more than 90% probability. The negative (-) predictive value of the testing is higher than 90% (11, 12) . The sensitivity of HPV DNA testing in HGSIL HPV (+) patients is 98%. Also, 20-40% of precancerous lesions can not be detected by colposcopy, even by the most experienced specialist. HPV testing in this patient group will be a guide in patient follow-up. While a negative test result supports the lack of detection of lesion by colposcopy, a positive test result will suggest the presence of risk and show that the colposcopy result is a false negative (13) .
Abnormal Cervical Smear Management Squamous cell abnormalities A. Unsatisfactory cytology
When all cytological methods are included, the probability of unsatisfactory cytology is less than 1%. This result is unreliable in the detection of epithelial abnormalities (14, 15) . The most common reason for this unsatisfactory cytology is the insufficient squamous cell count (16) . Management of unsatisfactory cytology is presented in Figure 1 .
B. Cytology reported as negative but with absent or insufficient endocervical and transformation zone
Cytology that is reported as negative but with an absent or insufficient endocervical and transformation zone has adequate cellularity for interpretation but lacks endocervical or metaplastic cells, suggesting that the squamocolumnar junction may not have been adequately sampled. Recent publications report that this cytological abnormality has ranged from 10% to 20% and is higher in older women (17, 18) . The management of this cytological abnormality, which was recently recommended for early repeat cytology, has changed as indicated in Figure 2 .
C. Negative cytology with a positive HPV test
Recently, co-testing is the preferred screening strategy for women aged 30-64 years and is not indicated for younger women (19) . Despite negative cytology, women with HPV are at higher risk for later CIN 3 than women with negative HPV tests (20) . Management of cases with negative cytology but with a positive HPV test is presented in Figure 3 . 
D. ASC-US

. ASC-US management
HPV DNA testing is negative, patient should be followed up with yearly control. If HPV DNA testing is positive, patients are referred for colposcopy and managed according to the results. If HPV DNA testing is not possible, colposcopic examination will be performed; if it is normal, the patient will be called periodically with yearly controls until the smear becomes normal.
If an abnormal lesion is detected by colposcopy, immediate treatment is necessary. The related algorithm is presented in Figures 5-7 .
E. ASC-H ASC-H confers higher risk for CIN 3 over time than ASC-US or
LGSIL. Reflex HPV testing is not recommended in ASC-H due to high HPV prevalence. In addition, the 5-year cancer risk among women with HPV-negative ASC-H is 2%, which is too high to justify observation (Figure 8, 9 ).
F. HGSIL
It should be treated. Laser or loop, which has equal success, can be applied. Cold-knife conization is one the methods. Unsuccessful results are due to non-compliance with the protocol. The skill and knowledge of the gynecologist are more important for the success than the method (21) (22) (23) (24) . Endocervical assessment is important here. HPV testing can be useful in the follow-up; however, it will not be as important as it is for LGSIL.
Colposcopy constitutes one of the main steps. Biopsy will be necessary in the presence of abnormal colposcopic findings, and the treatment of the lesion will be based accordingly (Figure 9, 10) . In 2013, the ASCCP published 2012 consensus results about CINs based on the histological diagnosis following the consensus regarding the management of cervical cytological abnormalities (25) . The recommendation for CIN 1 is followup without treatment. However, treatment is also an acceptable option. In the follow-up without treatment, in addition to HPV DNA testing, one of the options, which are cytology and colposcopy, can be used. The related flow-chart is presented tive treatments in HIV (+) patients using immunosuppressive agents (25) . Follow-up is more recommended for adolescents with CIN 2, as it is in CIN 1.
Glandular cell abnormalities A. Atypical glandular cells (AGC)
Atypical glandular cells have been associated with polyps and metaplasia but also with neoplasias, including adenocarcinomas of the endometrium, cervix, ovary, fallopian tube, and other sites. Although the cancer risk is lower in women younger than 35 years of age, the risk of CIN 2 and higher lesions is increased at all ages (26) . AGC cytology is most commonly associated with squamous lesions, including CIN 1. For women with all subcategories, except atypical endometrial cells, colposcopy with endocervical sampling is recommended in all subcategories. Endometrial sampling is recommended in women 35 years of age and older or with abnormal bleeding in all subcategories. The treatment algorithm is presented in Figures 16 and 17 .
B. Adenocarcinoma in situ
In adenocarcinoma in situ (AIS), endocervical glandular cells are replaced by nuclear stratification, hyperchromasia, irregularities, and long columnar cells with increased mitotic activity (27) (28) (29) . Cell proliferation leads to overcrowded and punched glands. However, the normal branching pattern of the endocervical glands is reached as well. Most neoplastic cells resemble those of the endocervical mucinous epithelium. Endometrioid and intestinal cell types appear less often. Squamous CIN is observed in 50% of the women with cervical AIS. So, some of the AIS lesions represent the findings in the samples obtained for squamous neoplasia treatment. As AIS is near or above the transformation zone, traditional cervical samples may not be effective in AIS sampling. Sampling via Cytobrush may enhance AIS screening. If the AIS focus is small, the findings of cervical biopsy and endocervical curettage may be negative. A more comprehensive cervical examination in conization form is necessary for such cases. With such a sample, it is also possible to exclude invasive adeno- The term "microinvasion" should not be used in adenocarcinoma definitions. Once it spreads to glands, there is no clear technique to determine the true "depth of invasion," because the invasion may have originated from the mucosal surface or from exterior surface of the glands. "Passing" through the basal membrane can not be described completely; therefore, the tumor is either adenocarcinoma in situ or invasive adenocarcinoma.
With the recent increase in endocervical invasive adenocarcinoma, adenocarcinoma in situ has been noticed more. There is evidence that adenocarcinoma in situ can progress to cancer. Boone (30) reported 52 cervical adenocarcinoma cases where 18 endocervical biopsy results were interpreted as negative 3-7 years before cancer developed. Adenocarcinoma was detected among five of them. Muntz (31) reported 40 cases with AIS who also had cervical conization. Coexisting squamous cell carcinoma was observed in 23 (53%) of these 40 patients. In 10 of the 22 patients who had undergone hysterectomy, margins of coni specimens were positive and 70% had remaining AIS. Additionally, two patients had invasive adenocarcinoma. Among the 12 patients with negative margins, focal adenocarcinoma in the hysterectomy specimen was seen in one of them. In 18 women, only conization with negative margins was detected, and the disease did not recurr after 3 years on average. So, positive margins in conization specimens were significant findings for these patients. Pyonor et al. (32) reported the results of another more interesting study of 28 patients with AIS. Among the 8 patients with positive margins who had undergone repeat conization or hysterectomy, residual AIS was detected in 3 and invasive adenocarcinoma was detected in 1. Of the 10 patients with negative margins who had undergone hysterectomy or repeat conization, 4 had residual AIS. Invasive adenocarcinoma was detected in 1 patient, whose cone margin had not been examined. Among 15 patients treated with repeat cervical conization and close follow-up, recurrent glandular lesions, detected as a result of conization, were found in 7 patients (47%), and in 2 of them, invasive adenocarcinoma was detected. Furthermore, 48% of the patients were not suspected to have glandular lesions based on their endocervical curettage and Pap smear test results obtained before conization. Adenocarcinoma in situ has to be regarded as a significant adenocarcinoma cancer precursor. The entire endocervical canal is under risk, and examination of lesion by cytology and curettage procedures may be unreliable. Repeat conizations should be performed in patients with positive cone margins. If fertility can be disregarded, hysterectomy should be done, even in the case of a negative margin due to the risk of recurrence ( Figure 18 ).
The NCCN Guidelines Panel for Cervical Cancer Screening endorses the 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors (25) .
Evaluation of Intraepithelial Lesions During Pregnancy
Cervical cancer is the most common malignancy during pregnancy. It is relatively rare in developed countries. It is due to the low cancer incidence, depending on low birth rate and routine cervical cytological screening programs. Its incidence is 1-13/10,000. This equals the incidence of 1 cervical cancer in 2000-2500 pregnancies and 1 CIN 3 in 750 pregnancies. Pregnancy was present in about 1% of the women with cervical cancer at the time of diagnosis. Most of the cases are asymptomatic. Therefore, the diagnosis is often delayed. Patients who experience vaginal bleeding during pregnancy and those with post-coital bleeding should be screened for cervical cancer, and speculum examination should definitely be performed in these patients. Pregnancy does not affect the prognosis of cervical cancer (33, 34) . The cervix is soft and hypertrophic during pregnancy and usually moves towards the columnar epithelial porsio. Therefore, unsatisfactory cytology and colposcopy are rare. In the study of Baldauf et al. (35) regarding the management of 140 pregnant women with abnormal smear results, it was found that colposcopy was adequate in 86% of the patients, compatible with 69% biopsy diagnosis, 18% false positive, and 13% false negative rates. Biopsy was performed in 115 patients, and bleeding was noted in only 1 patient. They concluded that colposcopy and accompanying biopsy are reliable procedures in the management of abnormal smears. Further, 86% of the cervical abnormalities during pregnancy are LGSIL, and most of them are caused by HPV. The remaining 14% are HGSIL. Hormonal and vascular changes during pregnancy do not interfere with the natural progress of invasive cervical cancer. There is no evidence showing faster progression of CIN to invasive cancer during pregnancy.
In conclusion, it should be noted that the goal during pregnancy is not to diagnose and follow up preinvasive lesions or not to treat Figure 18 . AIS management
